Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

BOOSTRIX 2 UNIT / 0.5 ML

DIPHTHERIA TOXOID : 2 UNIT / 0.5 ML PERTUSSIS TOXOID : 8 MCG / 0.5 ML FILAMENTOUS HAEMAGGLUTININ : 8 MCG / 0.5 ML TETANUS TOXOID : 20 UNIT / 0.5 ML PERTACTIN : 2.5 MCG / 0.5 ML · DIN 02247600 · GLAXOSMITHKLINE INC

Health Canada status: MARKETED

What is BOOSTRIX?

BOOSTRIX 2 UNIT / 0.5 ML contains DIPHTHERIA TOXOID : 2 UNIT / 0.5 ML PERTUSSIS TOXOID : 8 MCG / 0.5 ML FILAMENTOUS HAEMAGGLUTININ : 8 MCG / 0.5 ML TETANUS TOXOID : 20 UNIT / 0.5 ML PERTACTIN : 2.5 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02247600, held by GLAXOSMITHKLINE INC, supplied as SUSPENSION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 29-May-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is BOOSTRIX used for?

BOOSTRIX (combined diphtheria, tetanus, acellular pertussis (adsorbed) vaccine) is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals from the age of four years onwards, and for passive protection against pertussis in early infancy following maternal immunisation during pregnancy.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02247600
Brand nameBOOSTRIX
Generic / active ingredientDIPHTHERIA TOXOID : 2 UNIT / 0.5 ML PERTUSSIS TOXOID : 8 MCG / 0.5 ML FILAMENTOUS HAEMAGGLUTININ : 8 MCG / 0.5 ML TETANUS TOXOID : 20 UNIT / 0.5 ML PERTACTIN : 2.5 MCG / 0.5 ML
ManufacturerGLAXOSMITHKLINE INC
Strength2 UNIT / 0.5 ML
Dosage formSUSPENSION
Route of administrationINTRAMUSCULAR
ScheduleSchedule D
ATC codeJ07AX OTHER BACTERIAL VACCINES
AHFS class80:08.00 ; 80:12.00
BiosimilarNo
Health Canada statusMARKETED
Status date29-May-2007
Original market date2007-05-29 00:00:00

How is it administered?

Single 0.5 mL dose by deep intramuscular injection. Not for primary immunization. Booster intervals generally every 10 years. Can be given during third trimester of pregnancy.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

null

How is it supplied?

prefilled syringes (type I glass) with a plunger stopper (butyl rubber) and with a rubber tip cap (in packages of 10).

Contraindications

Hypersensitivity to components; encephalopathy within 7 days of previous pertussis vaccine; transient thrombocytopenia or neurological complications after previous diphtheria/tetanus vaccination.

Warnings and precautions

Not for IV use. Postpone in acute severe febrile illness. Potential risk of Guillain-Barré Syndrome or brachial neuritis. Caution in individuals with bleeding disorders/thrombocytopenia.

What can be used instead?

Other Canadian products sharing ATC code J07AX OTHER BACTERIAL VACCINES. 1 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
LYMERIX30 MCG / 0.5 MLLIQUIDGLAXOSMITHKLINE INCCANCELLED POST MARKETDIN 02239195
MEGAVAC INJ75 MLIQUIDOMEGA LABORATORIES LIMITEDCANCELLED POST MARKETDIN 00316393
MRV200 MSUSPENSIONHOLLISTER-STIER LABORATORIES LLCCANCELLED POST MARKETDIN 02216981

Who else supplies OTHER BACTERIAL VACCINES worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. OTHER BACTERIAL VACCINES appears in 8 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for BOOSTRIX

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for BOOSTRIX

Health Canada Drug Product Database (DPD), DIN 02247600. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.